<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>44</viewCount><searchCount>0</searchCount></scores><additional><submitter>Lukens JR</submitter><funding>European Research Council</funding><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIAMS NIH HHS</funding><pagination>654-64</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4412374</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>42(4)</volume><pubmed_abstract>Missense mutations in the nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing family of gene 12 (Nlrp12) are associated with periodic fever syndromes and atopic dermatitis in humans. Here, we have demonstrated a crucial role for NLRP12 in negatively regulating pathogenic T cell responses. Nlrp12(-/-) mice responded to antigen immunization with hyperinflammatory T cell responses. Furthermore, transfer of CD4(+)CD45RB(hi)Nlrp12(-/-) T cells into immunodeficient mice led to more severe colitis and atopic dermatitis. NLRP12 deficiency did not, however, cause exacerbated ascending paralysis during experimental autoimmune encephalomyelitis (EAE); instead, Nlrp12(-/-) mice developed atypical neuroinflammatory symptoms that were characterized by ataxia and loss of balance. Enhanced T-cell-mediated interleukin-4 (IL-4) production promotes the development of atypical EAE disease in Nlrp12(-/-) mice. These results define an unexpected role for NLRP12 as an intrinsic negative regulator of T-cell-mediated immunity and identify altered NF-?B regulation and IL-4 production as key mediators of NLRP12-associated disease.</pubmed_abstract><journal>Immunity</journal><pubmed_title>The NLRP12 Sensor Negatively Regulates Autoinflammatory Disease by Modulating Interleukin-4 Production in T Cells.</pubmed_title><pmcid>PMC4412374</pmcid><funding_grant_id>R01 AR056296</funding_grant_id><funding_grant_id>P30 CA021765</funding_grant_id><funding_grant_id>281600</funding_grant_id><funding_grant_id>AR056296</funding_grant_id><funding_grant_id>AI101935</funding_grant_id><funding_grant_id>R01 CA163507</funding_grant_id><funding_grant_id>CA163507</funding_grant_id><funding_grant_id>R01 AI101935</funding_grant_id><pubmed_authors>Lukens JR</pubmed_authors><pubmed_authors>Barr MJ</pubmed_authors><pubmed_authors>Gurung P</pubmed_authors><pubmed_authors>Shaw PJ</pubmed_authors><pubmed_authors>Brown SA</pubmed_authors><pubmed_authors>Kanneganti TD</pubmed_authors><pubmed_authors>Vogel P</pubmed_authors><pubmed_authors>Zaki MH</pubmed_authors><pubmed_authors>Chi H</pubmed_authors><view_count>44</view_count></additional><is_claimable>false</is_claimable><name>The NLRP12 Sensor Negatively Regulates Autoinflammatory Disease by Modulating Interleukin-4 Production in T Cells.</name><description>Missense mutations in the nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing family of gene 12 (Nlrp12) are associated with periodic fever syndromes and atopic dermatitis in humans. Here, we have demonstrated a crucial role for NLRP12 in negatively regulating pathogenic T cell responses. Nlrp12(-/-) mice responded to antigen immunization with hyperinflammatory T cell responses. Furthermore, transfer of CD4(+)CD45RB(hi)Nlrp12(-/-) T cells into immunodeficient mice led to more severe colitis and atopic dermatitis. NLRP12 deficiency did not, however, cause exacerbated ascending paralysis during experimental autoimmune encephalomyelitis (EAE); instead, Nlrp12(-/-) mice developed atypical neuroinflammatory symptoms that were characterized by ataxia and loss of balance. Enhanced T-cell-mediated interleukin-4 (IL-4) production promotes the development of atypical EAE disease in Nlrp12(-/-) mice. These results define an unexpected role for NLRP12 as an intrinsic negative regulator of T-cell-mediated immunity and identify altered NF-?B regulation and IL-4 production as key mediators of NLRP12-associated disease.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Apr</publication><modification>2020-10-29T10:00:08Z</modification><creation>2019-03-27T01:50:38Z</creation></dates><accession>S-EPMC4412374</accession><cross_references><pubmed>25888258</pubmed><doi>10.1016/j.immuni.2015.03.006</doi></cross_references></HashMap>